X

Drug Profile

ADX 631

Alternative Names: ADX-631

Latest Information Update: 09 Jul 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aldeyra Therapeutics
Class Anti-inflammatories; Eye disorder therapies
Mechanism of Action Aldehyde modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Dry age-related macular degeneration

Most Recent Events

20 Jun 2024 Preclinical trials in Dry age-related macular degeneration in USA (Intravitreous) prior to June 2024
20 Jun 2024 In June 2024, Aldeyra Therapeutics plans to submit an IND application for ADX 631 for the treatment of dry AMD or geographic atrophy in the first half of 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com